Utility of Tc-99m GSA whole-body scintigraphy in detecting bone metastases from hepatocellular carcinoma

被引：3

作者：

Sueyoshi, K ^{[1
]}

Narabayashi, I ^{[1
]}

Aratani, T ^{[1
]}

Doi, K ^{[1
]}

Komori, T ^{[1
]}

Ogura, Y ^{[1
]}

Utsunomiya, K ^{[1
]}

Shimidzu, T ^{[1
]}

机构：

[1] Osaka Med Coll, Dept Radiol, Takatuki, Osaka 5698686, Japan

来源：

CLINICAL NUCLEAR MEDICINE | 2001年 / 26卷 / 03期

关键词：

bone metastases; bone scintigraphy; hepatocellular carcinoma; Tc-99m GSA whole-body scintigraphy; Tc-99m PMT whole-body scintigraphy;

D O I：

10.1097/00003072-200103000-00008

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

Recent advances in the treatment of hepatocellular carcinoma (HCC) have prolonged patient survival, However, the number of patients with bone metastases identified during follow-up examinations has increased. Tc-99m Sn-N-pyridoxy-5-methyltryptophan (Tc-99m PMT) has been reported to accumulate at a high rate in HCC lesions and bone metastases, In the patient described here, whole-body scintigraphy showed accumulation of DTPA galactosyl human serum albumin (Tc-99m GSA) and Tc-99m PMT in bone metastases from HCC. The authors suggest that asialoglycoprotein receptors may be present in bone metastases from well-differentiated HCC, Tc-99m GSA whole-body imaging can be used to detect bone metastases from HCC and to evaluate hepatic reserve.

引用

页码：221 / 224

页数：4

共 16 条

[1]

GEORGEN TG, 1974, J NUCL MED, V15, P1120

[2]

HASEGAWA Y, 1985, EUR J NUCL MED, V10, P255

[3]

HYODO I, 1993, LIVER, V13, P80

[4]

ISHIZU H, 1976, ACTA HEPATOL JAPAN, V17, P47

[5]

KODA M, 1994, HEPATO-GASTROENTEROL, V41, P25

[6]

KUDO M, 1991, J NUCL MED, V32, P1177

[7]

LIVRAGHI T, 1992, CANCER, V69, P925, DOI 10.1002/1097-0142(19920215)69:4<925::AID-CNCR2820690415>3.0.CO

[8]

2-G

[9]

Miki K, 1997, J NUCL MED, V38, P1798

[10]

NAKANISHI Y, 1992, Nippon Acta Radiologica, V52, P208

← 1 2 →